2024
An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study
Dunn W, Li Y, Singal A, Simonetto D, Díaz L, Idalsoaga F, Ayares G, Arnold J, Ayala-Valverde M, Perez D, Gomez J, Escarate R, Fuentes-López E, Ramirez-Cadiz C, Morales-Arraez D, Zhang W, Qian S, Ahn J, Buryska S, Mehta H, Dunn N, Waleed M, Stefanescu H, Bumbu A, Horhat A, Attar B, Agrawal R, Cabezas J, Echavaría V, Cuyàs B, Poca M, Soriano G, Sarin S, Maiwall R, Jalal P, Higuera-de-la-Tijera F, Kulkarni A, Rao P, Guerra-Salazar P, Skladaný L, Kubánek N, Prado V, Clemente-Sanchez A, Rincon D, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jiménez C, Hudson D, García-Tsao G, Ortiz G, Abraldes J, Kamath P, Arrese M, Shah V, Bataller R, Arab J. An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study. Hepatology 2024, 80: 1196-1211. PMID: 38607809, DOI: 10.1097/hep.0000000000000883.Peer-Reviewed Original ResearchAlcohol-associated hepatitisValidation cohortArtificial intelligenceModified Glasgow scoreMaddrey's discriminant functionMortality rateGlobal cohort studyShort-term mortalityPost-test probabilityApproximate mortality ratesSteroid therapyGlasgow scoreAH patientsSteroid useTransplant indicationRetrospective studyDerivation cohortLaboratory valuesCohort studyClinical trialsGlobal cohortPrognostic modelScoring systemAI algorithmsCohortP-19 CHARACTERIZATION, PROGNOSTIC FACTORS, AND SURVIVAL IN MODERATE ALCOHOL-ASSOCIATED HEPATITIS: A MULTICENTER STUDY
Idalsoaga F, Díaz L, Corsi O, Ayares G, Arnold J, Dunn W, Li Y, Singal A, Simonetto D, Ayala-Valverde M, Ramirez C, Morales-Arraez D, Zhang W, Qian S, Ahn J, Buryska S, Mehta H, Waleed M, Stefanescu H, Horhat A, Bumbu A, Attar B, Agrawal R, Cabezas J, Cuyàs B, Poca M, Pastor G, Sarin S, Maiwall R, Jalal P, La Tijera M, Kulkarni A, Rao N, Salazar P, Skladaný L, Bystrianska N, Prado V, Clemente-Sanchez A, Rincón D, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jimenez C, García-Tsao G, Ortiz G, Abraldes J, Kamath P, Shah V, Bataller R, Arab J. P-19 CHARACTERIZATION, PROGNOSTIC FACTORS, AND SURVIVAL IN MODERATE ALCOHOL-ASSOCIATED HEPATITIS: A MULTICENTER STUDY. Annals Of Hepatology 2024, 29: 101206. DOI: 10.1016/j.aohep.2023.101206.Peer-Reviewed Original ResearchRenal replacement therapyVariables associated with mortalityModerate AHAlcohol-associated hepatitisPrognostic factorsLiver transplantationMaddrey's discriminant functionAssociated with high mortalityMultiple organ failureRetrospective cohort studyMultivariate-adjusted modelsShort-term mortalityAssociated with mortalityCompeting-risks modelMedian ageCause of deathReplacement therapyMulticenter studyMELD scoreOrgan failureUnivariate analysisCohort studyFrequent causeSevere entitySurvival rateP- 40 PENTOXIFYLLINE USE IN PATIENTS WITH ALCOHOL-ASSOCIATED HEPATITIS ADMITTED WITH ACUTE KIDNEY INJURY COULD DECREASE SURVIVAL: A GLOBAL STUDY
Idalsoaga F, Diaz L, Corsi O, Ayares G, Arnold J, Dunn W, Li Y, Singal A, Simonetto D, Ayala-Valverde M, Ramirez C, Morales-Arraez D, Zhang W, Qian S, Ahn J, Buryska S, Mehta H, Waleed M, Stefanescu H, Horhat A, Bumbu A, Agrawal B, Agrawal R, Cabezas J, Cuyàs B, Poca M, Pastor G, Sarin S, Maiwall R, Jalal P, La Tijera M, Kulkarni A, Rao N, Salazar P, Skladaný L, Bystrianska N, Prado V, Clemente-Sanchez A, Rincón D, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jimenez C, García-Tsao G, Ortiz G, Abraldes J, Kamath P, Shah V, Bataller R, Arab J. P- 40 PENTOXIFYLLINE USE IN PATIENTS WITH ALCOHOL-ASSOCIATED HEPATITIS ADMITTED WITH ACUTE KIDNEY INJURY COULD DECREASE SURVIVAL: A GLOBAL STUDY. Annals Of Hepatology 2024, 29: 101227. DOI: 10.1016/j.aohep.2023.101227.Peer-Reviewed Original ResearchAlcohol-associated hepatitisAcute kidney injurySevere AHPentoxifylline useLiver transplantationKidney injuryMaddrey's discriminant functionAssociated with increased mortalityHistory of cirrhosisSubgroup of patientsRetrospective cohort studyMultivariate-adjusted modelsEffect of pentoxifyllineAssociated with mortalityCompeting-risks modelMedian ageSerum creatinineMELD scoreUnivariate analysisCohort studyFemale sexPentoxifyllineDecreased survivalSevere entityPatients
2023
Further decompensation in cirrhosis: Results of a large multicenter cohort study supporting Baveno VII statements
D’Amico G, Zipprich A, Villanueva C, Sordà J, Morillas R, Garcovich M, Retortillo M, Martinez J, Calès P, D’Amico M, Dollinger M, García-Guix M, Ballerga E, Tsochatzis E, Cirera I, Albillos A, Roquin G, Pasta L, Colomo A, Daruich J, Canete N, Boursier J, Dallio M, Gasbarrini A, Iacobellis A, Gobbo G, Merli M, Federico A, Baroni G, Pozzoni P, Addario L, Chessa L, Ridola L, Garcia-Tsao G. Further decompensation in cirrhosis: Results of a large multicenter cohort study supporting Baveno VII statements. Hepatology 2023, 79: 869-881. PMID: 37916970, DOI: 10.1097/hep.0000000000000652.Peer-Reviewed Original ResearchMulticenter cohort studyFurther decompensationLiver transplantFirst decompensationCumulative incidenceCohort studyLarge multicenter cohort studyCause-specific Cox modelsFive-year probabilityHazard ratioPrognostic weightPrognostic indicatorDecompensationCirrhosisCox modelPatientsAdvanced stageTransplantIncidenceMortalityDeathAscitesComplicationsMonthsLBP-09 Further decompensation as a new prognostic stage in cirrhosis. Results of a large multicenter cohort study supporting Baveno VII statements
D’Amico G, Garcia-Tsao G, Zipprich A, Villanueva C, Sorda J, Morillas R, Garcovich M, García-Retortillo M, Martinez J, Cales P, D’Amico M, Dollinger M, Garcia-Guix M, Ballerga E, Tsochatzis E, Cirera I, Albillos A, Roquin G, Pasta L, Colomo A, Hidalgo N, Boursier J, Dallio M, Gasbarrini A, Angelo I, Gobbo G, Merli M, Federico A, Svegliati-Baroni G, Pozzoni P, Addario L, Chessa L, Ridola L, Burroughs A. LBP-09 Further decompensation as a new prognostic stage in cirrhosis. Results of a large multicenter cohort study supporting Baveno VII statements. Journal Of Hepatology 2023, 78: s105-s106. DOI: 10.1016/s0168-8278(23)00591-3.Peer-Reviewed Original ResearchMedications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis
Rabiee A, Mahmud N, Falker C, Garcia-Tsao G, Taddei T, Kaplan D. Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis. Hepatology Communications 2023, 7: e0093. PMID: 36972386, PMCID: PMC10043587, DOI: 10.1097/hc9.0000000000000093.Peer-Reviewed Original ResearchConceptsAlcohol-associated cirrhosisAlcohol use disorderUse disordersCause mortalityImproved survivalPropensity scoreInpatient diagnosis codesRetrospective cohort studyCox regression analysisActive alcohol useCirrhosis decompensationCohort studyConcurrent diagnosisLiver diseasePotential confoundersDiagnosis codesVeteran outcomesCirrhosis diagnosisStrong negative predictorCirrhosisPatientsHazardous drinkingAlcohol use behaviorsCosts AssociatedAlcohol useMELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis
Díaz L, Fuentes-López E, Ayares G, Idalsoaga F, Arnold J, Valverde M, Perez D, Gómez J, Escarate R, Villalón A, Ramírez C, Hernandez-Tejero M, Zhang W, Qian S, Simonetto D, Ahn J, Buryska S, Dunn W, Mehta H, Agrawal R, Cabezas J, García-Carrera I, Cuyàs B, Poca M, Soriano G, Sarin S, Maiwall R, Jalal P, Abdulsada S, Higuera-de-la-Tijera F, Kulkarni A, Rao P, Salazar P, Skladaný L, Bystrianska N, Clemente-Sanchez A, Villaseca-Gómez C, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Castro-Sanchez S, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jiménez C, Louvet A, García-Tsao G, Roblero J, Abraldes J, Shah V, Kamath P, Arrese M, Singal A, Bataller R, Arab J. MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis. JHEP Reports 2023, 5: 100727. PMID: 37456675, PMCID: PMC10339256, DOI: 10.1016/j.jhepr.2023.100727.Peer-Reviewed Original ResearchRenal replacement therapy requirementAlcohol-associated hepatitisMaddrey's discriminant functionShort-term mortalityFurther prospective studiesMELD-NaTherapy requirementsProspective studyEnd-stage liver diseaseHigh short-term mortalityGlobal cohortRetrospective cohort studyCompeting-risk analysisTime-dependent AUCMELD-sodiumLiver transplantationMalnourished patientsCohort studyEstablishment of treatmentLiver diseaseABIC scoreLargest global cohortMAIN OUTCOMEMortality predictionDeLong methodO-25 ASSESSMENT OF MODELS FOR PREDICTING RESPONSE TO CORTICOIDS TREATMENT IN ALCOHOL-ASSOCIATED HEPATITIS: A GLOBAL COHORT STUDY
Idalsoaga F, Díaz L, Ayares G, Arnold J, Dunn W, Li Y, Singal A, Simonetto D, Ayala-Valverde M, Perez D, Gomez J, Escarate R, Fuentes-López E, Ramirez C, Morales-Arraez D, Zhang W, Qian S, Ahn J, Buryska S, Mehta H, Waleed M, Stefanescu H, Horhat A, Bumbu A, Attar B, Grawal R, Cabezas J, García-Carrera I, Cuyàs B, Poca M, Pastor G, Sarin S, Maiwall R, Jalal P, La Tijera M, Kulkarni A, P N, Salazar P, Skladaný L, Bystrianska N, Prado V, Clemente-Sanchez A, Rincón D, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jimenez C, García-Tsao G, Ortiz G, Abraldes J, Kamath P, Arrese M, Shah V, Bataller R, Arab J. O-25 ASSESSMENT OF MODELS FOR PREDICTING RESPONSE TO CORTICOIDS TREATMENT IN ALCOHOL-ASSOCIATED HEPATITIS: A GLOBAL COHORT STUDY. Annals Of Hepatology 2023, 28: 101035. DOI: 10.1016/j.aohep.2023.101035.Peer-Reviewed Original ResearchCox regressionSevere AHCohort studyHigh mortalityAlcohol‐Associated HepatitisRetrospective cohort studyKaplan-Meier curvesShort-term mortalityGlobal cohort studyLille modelMultivariable analyzesCorticosteroid treatmentMELD scoreAH patientsSevere entitySerum bilirubinClinical variablesBetter prognosticationWorldwide cohortSevere diseasePatientsDay 7Predicting ResponseDay 4Corticosteroids
2022
Role of Oral Health, Frailty, and Minimal Hepatic Encephalopathy in the Risk of Hospitalization: A Prospective Multi-Center Cohort of Outpatients With Cirrhosis
Bajaj J, Lai J, Tandon P, O'Leary J, Wong F, Garcia-Tsao G, Vargas H, Kamath P, Biggins S, Limon-Miro A, Shaw J, Mbachi C, Chew M, Golob Deeb J, Thacker L, Reddy K. Role of Oral Health, Frailty, and Minimal Hepatic Encephalopathy in the Risk of Hospitalization: A Prospective Multi-Center Cohort of Outpatients With Cirrhosis. Clinical Gastroenterology And Hepatology 2022, 21: 1864-1872.e2. PMID: 36328307, PMCID: PMC11057906, DOI: 10.1016/j.cgh.2022.10.023.Peer-Reviewed Original ResearchConceptsPoor oral healthOral healthMulti-center cohortCirrhosis detailsComorbid conditionsLiver diseaseEnd-stage liver diseaseMulti-center cohort studyRisk of hospitalizationPortal hypertensive complicationsMinimal hepatic encephalopathyNew study cohortMulti-variable analysisCirrhosis complicationsNonelective hospitalizationPeriodontitis historyPrior HEFrailty assessmentFrailty scoreHypertensive complicationsCohort studyHepatic encephalopathyStudy cohortRisk factorsCirrhosis
2020
SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension
Saffo S, Garcia‐Tsao G, Taddei T. SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension. Journal Of Diabetes 2020, 13: 265-269. PMID: 33210815, DOI: 10.1111/1753-0407.13136.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBenzhydryl CompoundsCohort StudiesDiabetes Mellitus, Type 2FemaleGlucosidesGlycated HemoglobinHumansHypertension, PortalLiver CirrhosisMaleMiddle AgedOutcome Assessment, Health CarePolyuriaSodium-Glucose Transporter 2 InhibitorsTertiary Care CentersUrinary Tract InfectionsYoung AdultConceptsSGLT2 inhibitorsPortal hypertensionDiabetes mellitusSodium-glucose cotransporter 2 inhibitorsGlucose cotransporter 2 inhibitorsCenter cohort studyCotransporter 2 inhibitorsCohort of patientsPotential therapeutic targetFavorable pleiotropic effectsCohort studyRenal diseaseClinical trialsClinical dataTherapeutic targetPatientsCirrhosisHypertensionMellitusOngoing evaluationInhibitorsPleiotropic effectsCohortDiseaseTrials
2016
Impact of Treatment of Non-bleeding Complications of Cirrhosis on the Risk of Variceal Bleeding
Augustin S, Albillos A, Ripoll C, Abraldes J, Salerno F, Moreau R, Reiberger T, Garcia-Tsao G. Impact of Treatment of Non-bleeding Complications of Cirrhosis on the Risk of Variceal Bleeding. 2016, 341-353. DOI: 10.1007/978-3-319-23018-4_34.Peer-Reviewed Original ResearchHepatic venous pressure gradientVariceal hemorrhageVariceal bleedingPortal pressureAlpha-1 adrenergic antagonistNon-bleeding complicationsVenous pressure gradientPortal blood flowClinical trial recordsImpact of treatmentDecompensated cirrhosisOral anticoagulantsRefractory ascitesCirrhotic patientsClinical decompensationCohort studyArterial pressureVasoactive drugsRandomized trialsLarge trialsCardiac outputProphylactic useAdrenergic antagonistsClinical dataBlood flow
2014
Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury
Belcher JM, Sanyal AJ, Peixoto AJ, Perazella MA, Lim J, Thiessen‐Philbrook H, Ansari N, Coca SG, Garcia‐Tsao G, Parikh CR, Consortium F. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology 2014, 60: 622-632. PMID: 24375576, PMCID: PMC4065642, DOI: 10.1002/hep.26980.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAcute-Phase ProteinsAdultAgedAlbuminuriaBiomarkersCreatinineDiagnosis, DifferentialFatty Acid-Binding ProteinsFemaleGlomerular Filtration RateHepatitis A Virus Cellular Receptor 1HumansInterleukin-18KidneyLipocalin-2LipocalinsLiver CirrhosisMaleMembrane GlycoproteinsMiddle AgedProspective StudiesProto-Oncogene ProteinsReceptors, VirusSodiumConceptsAcute kidney injuryAcute tubular necrosisKidney injury molecule-1Neutrophil gelatinase-associated lipocalinHepatorenal syndromePrerenal azotemiaKidney injuryDifferential diagnosisUrinary biomarkersEtiology of AKIProgressive acute kidney injuryLiver-type fatty acidOptimal diagnostic cutoffInjury molecule-1Prospective cohort studyGelatinase-associated lipocalinAccurate differential diagnosisClinical decision makingNumber of biomarkersCohort studyTubular necrosisFractional excretionCommon etiologyInterleukin-18Kidney biomarkersNovel inflammatory biomarkers of portal pressure in compensated cirrhosis patients
Buck M, Garcia‐Tsao G, Groszmann RJ, Stalling C, Grace ND, Burroughs AK, Patch D, Matloff DS, Clopton P, Chojkier M. Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients. Hepatology 2014, 59: 1052-1059. PMID: 24115225, DOI: 10.1002/hep.26755.Peer-Reviewed Original ResearchConceptsHepatic vein pressure gradientGastroesophageal varicesCirrhosis patientsUnnecessary esophagogastroduodenoscopyPortal hypertensionInflammatory biomarkersMultivariate logistic regression analysisInflammatory serum biomarkersNovel inflammatory biomarkerSerum VCAM-1Logistic regression analysisAssociated morbidityCohort studyPortal pressureLiver injuryBlood testsClinical parametersInflammatory pathwaysSerum biomarkersClinical trialsVCAM-1IL-1RPatientsDiagnostic testsMmHg
2012
Association of AKI With mortality and complications in hospitalized patients with cirrhosis
Belcher JM, Garcia‐Tsao G, Sanyal AJ, Bhogal H, Lim JK, Ansari N, Coca SG, Parikh CR, Consortium F. Association of AKI With mortality and complications in hospitalized patients with cirrhosis. Hepatology 2012, 57: 753-762. PMID: 22454364, PMCID: PMC3390443, DOI: 10.1002/hep.25735.Peer-Reviewed Original ResearchConceptsAcute kidney injuryAcute Kidney Injury Network definitionAssociation of AKIDefinition of AKISeverity of AKIProgression of AKIProspective observational cohort studyAKIN stage 1Baseline renal functionObservational cohort studyIncidence of mortalityAKI criteriaAKI severityAKI stageAKIN criteriaAKIN stageHospital mortalityKidney injuryCohort studyDevastating complicationRenal functionHospitalized patientsImproved outcomesEarly diagnosisTimely treatment